Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells

Stem Cells Translational Medicine

Volumn 3, Issue 9, 2014, Pages 1023-1031

  Peng, Yanwen ^a   Chen, Xiaoyong ^a   Liu, Qifa ^b   Xu, Dijing ^a   Zheng, Haiqing ^a,c   Liu, Longshan ^d   Liu, Qiuli ^a   Liu, Muyun ^a   Fan, Zhiping ^b   Sun, Jing ^b   Li, Xiaobo ^a   Zou, Ruifeng ^a   Xiang, Andy Peng ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

B cell activating factor; B cell homeostasis; Chronic graft versus host disease; Mesenchymal stromal cells

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B7 ANTIGEN; BETA1 INTEGRIN; CALCINEURIN INHIBITOR; CD11B ANTIGEN; CD1D ANTIGEN; CD23 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; ENDOGLIN; HERMES ANTIGEN; IMMUNOGLOBULIN D; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THY 1 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; CD19+ B LYMPHOCYTE; CD27+ B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; LYMPHOCYTE; MALE; MEMORY CELL; MESENCHYMAL STROMA CELL; MONOCYTIC LEUKEMIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCLEROSIS; SKIN ULCER; ADOLESCENT; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; B-LYMPHOCYTE SUBSETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; YOUNG ADULT;

EID: 84906858055     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0001     Document Type: Article

References (43)

1. Bhatia S, Francisco L, CarterAet al. Latemortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study. Blood 2007;110:3784-3792.
2. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009;114:7-19.
3. Flowers ME, Inamoto Y, CarpenterPAet al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117:3214-3219.
4. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012;12:443-458.
5. Lawitschka A, Ball L, Peters C. Nonpharmacologic treatment of chronic graft-versushost disease in children and adolescents. Biol Blood Marrow Transplant 2012;18(suppl): S74-S81.
6. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012;10:709-716.
7. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506.
8. EnglishK, FrenchA, WoodKJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010;7:431-442.
9. Uccelli A, Prockop DJ. Why shouldmesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 2010;22:768-774.
10. Le Blanc K, Frassoni F, Ball L et al; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
11. Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011;22:257-262.
12. Martin PJ, Uberti JP, Soiffer RJ et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010;16(suppl 2): S169-S170.
13. Zhou H, Guo M, Bian C et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: Clinical report. Biol Blood Marrow Transplant 2010;16:403-412.
14. Weng JY, Du X, Geng SX et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010;45:1732-1740.
15. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
16. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 2008;42(suppl 1):S66-S69.
17. Bennett SR, Carbone FR, Toy T et al. B cells directly tolerize CD8(+) T cells. J Exp Med 1998;188:1977-1983.
18. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919-4927.
19. Kier P, Penner E, Bakos S et al. Autoantibodies in chronic GVHD: High prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990;6:93-96.
20. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011;244:115-133.
21. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013;131:959-971.
22. Mackay F, Figgett WA, Saulep D et al. Bcell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010;237:205-225.
23. Sarantopoulos S, Stevenson KE, Kim HT et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107-6114.
24. Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graftversus-host disease. Blood 2006;108:756-762.
25. Teshima T, Nagafuji K, HenzanH et al. Rituximab for the treatment of corticosteroidrefractory chronic graft-versus-host disease. Int J Hematol 2009;90:253-260.
26. Kim SJ, Lee JW, JungCWet al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graftversus-host disease: Results from a prospective, multicenter, phase II study. Haematologica 2010;95:1935-1942.
27. Sarantopoulos S, Stevenson KE, Kim HT et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011;117:2275-2283.
28. vanDorp S, ResemannH, te Boome L et al. The immunological phenotype of rituximabsensitive chronic graft-versus-host disease: A phase II study. Haematologica 2011;96:1380-1384.
29. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
30. Zhang AX, Yu WH, Ma BF et al. Proteomic identification of differently expressed proteins responsible for osteoblast differentiation from human mesenchymal stem cells. Mol Cell Biochem 2007;304:167-179.
31. Yu W, Chen Z, Zhang J et al. Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem 2008;310:11-18.
32. Li Q, Li L, Liu Y et al. Pleural fluid from tuberculous pleurisy inhibits the functions of T cells and the differentiation of Th1 cells via immunosuppressive factors. Cell Mol Immunol 2011;8:172-180.
33. Li L, Qiao D, Zhang X et al. The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells. Immunobiology 2011;216:477-484.
34. Sarantopoulos S, Stevenson KE, Kim HT et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865-3874.
35. Sanz I, Wei C, Lee FE et al. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.
36. Feng L, Li L, Liu Y et al. B lymphocytes that migrate to tuberculous pleural fluid via the SDF-1/CXCR4 axis actively respond to antigens specific for Mycobacterium tuberculosis. Eur J Immunol 2011;41:3261-3269.
37. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010;16(suppl): S146-S151.
38. Kim SJ, Won JH. B cell homeostasis and the development of chronic graft-versus-host disease: Implications for B cell-depleting therapy. Leuk Lymphoma 2012;53:19-25.
39. Patriarca F, Skert C, Sperotto A et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006;34: 389-396.
40. Greinix HT, Pohlreich D, Kouba M et al. Elevated numbers of immature/transitional CD21-B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:208-219.
41. Pallier A, Hillion S, DangerR et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010;78:503-513.
42. Newell KA, Asare A, Kirk AD et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010;120:1836-1847.
43. Allen JL, Fore MS, Wooten J et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012;120:2529-2536.